For adiponectin and prostate cancer incidence, exclusion of one study by Lopez Fontana et al.34 reduced heterogeneity amongst cross-sectional studies from 76.0% to 47.9% but did not materially change the effect estimate. Here, ADIPOQ is linked to prostate carcinoma.